Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 3/20 | 0.33 |
| ▸ | CENPE | Q02224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444577 | 0.94 | WDR5 (0.40) | WDR5EZH2ALDH1A1LMNAMAPT | |
| SCHEMBL5437380 | 0.93 | CENPE (0.38) | ALDH1A1CCR3CENPE | |
| SCHEMBL5446667 | 0.92 | EGLN1 (0.37) | WDR5EGLN1EZH2ALDH1A1LMNA | |
| SCHEMBL31060990 | 0.91 | AKR1B1 (0.36) | WDR5CENPE | |
| SCHEMBL4479511 | 0.91 | AKR1B1 (0.36) | WDR5CENPE | |
| SCHEMBL4488414 | 0.90 | AKR1B1 (0.35) | WDR5CENPE | |
| SCHEMBL5438067 | 0.90 | EGLN1 (0.36) | WDR5EGLN1 | |
| SCHEMBL5450208 | 0.89 | EGLN1 (0.37) | EGLN1ALDH1A1MEN1KMT2A | |
| SCHEMBL5445142 | 0.89 | EGLN1 (0.39) | EGLN1ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL5440602 | 0.89 | MAOB (0.41) | EZH2MAPTMEN1KMT2ACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | claimed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-7294623-B2 | Benzyl morpholine derivatives | ELI LILLY AND COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20060052377-A1 | Benzyl morpholine derivatives | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052377-A1 | Benzyl morpholine derivatives | AR, HRH1, HRH4 | WDR5 3144/4885EGLN1 803/4885EZH2 3073/4885 |
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | WDR5 1380/4885EGLN1 1645/4885EZH2 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.